Akira Science

Akira Science is an early-stage biotech firm based in Stockholm, founded in 2021, that is merging AI-driven discovery with advanced tissue engineering. The company's lead program, AkiMed™, is a bioresorbable breast implant aimed at addressing the significant unmet need in breast cancer reconstruction, offering a more natural and accessible alternative to current complex procedures. While positioned in the tissue engineering sector, their core description emphasizes an AI platform for therapeutic acceleration, indicating a dual focus on platform technology and product development. The company appears to be in a pre-clinical, pre-revenue stage, building its foundational technology and initial product candidate.

AI-driven platform for designing synthetic, bioresorbable polymers and 3D-printed scaffolds for soft tissue engineering. Focus on customizable material properties and patient-specific implant fabrication.

Competes with established medical device companies offering permanent breast implants (e.g., Allergan, Mentor) and emerging regenerative medicine approaches using acellular dermal matrices or fat grafting. Akira's proposed fully bioresorbable, 3D-printed scaffold is a novel approach, but faces competition from other startups in the 3D-bioprinting space.